<DOC>
	<DOCNO>NCT00666055</DOCNO>
	<brief_summary>The purpose research study learn level antiretroviral drug level response HIV virus genital tract woman post-menopausal . The investigator study think level hormone post-menopausal HIV-infected woman may body may affect level antiretroviral drug , therefore affect much HIV virus body . Since woman already go menopause different level hormone , estrogen , woman pre-menopausal , investigator would like check level antiretroviral drug blood , genital secretion , genital tissue .</brief_summary>
	<brief_title>Sex , Aging Antiretroviral Pharmacokinetics</brief_title>
	<detailed_description>Purpose : To longitudinally quantify systemic genital tract antiretroviral pharmacokinetics viral response HIV-infected post-menopausal woman . These parameter compare pre-menopausal woman determine absence presence estrogen influence treatment response infectiousness HIV . Participants : 30 post-menopausal 12 pre-menopausal HIV-infected woman Procedures ( method ) : First dose , steady state , longitudinal pharmacokinetics commonly prescribe antiretroviral agent assess systemic genital tract compartment cohort post- pre-menopausal HIV-infected woman . Concurrent blood plasma genital secretion HIV RNA measure . Systemic genital tract virologic response correlate antiretroviral concentration .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>1 . HIVinfected woman &gt; 18 year age 2 . There specific entry criterion CD4+ Tcell count plasma HIV RNA . 3 . Menopause status determine screen . 1 . Postmenopausal define cessation menses &gt; 12 month ( undergone bilateral oophorectomy without hysterectomy ) AND FSH &gt; 25 miu/mL estradiol level &lt; 20 pg/mL establish physiological biochemical evidence menopause . 2 . Premenopausal woman must regular cycle without perimenopausal vasomotor symptom receive exogenous hormone . 4 . Women may change new regimen virologic failure intolerability . Women resistance test available , two drug virus susceptible need include propose treatment regimen . 5 . Women may also na√Øve either NNRTI PIs initiate first , second third HAART regimen ( ARVs investigate : zidovudine , lamivudine , emtricitabine , abacavir , tenofovir , efavirenz , lopinavir/ritonavir , atazanavir without ritonavir ) . 6 . Provided ARV regimens contain one agent study may also include new agent maraviroc ( CCR5 inhibitor ) , raltegravir ( integrase inhibitor ) and/or etravirine ( NNRTI ) . Samples store pharmacokinetics agent evaluated future study assay available lab . 7 . Women must free sexually transmit infection ( STI 's ) time enrollment . 8 . Women must able abstain douche sexual activity 72 hour prior study visit . 9 . Subjects must willing genital tract sample take . 1 . Women currently receive medication know drugdrug interaction ARVs study . 2 . Women currently receive exogenous hormone therapy ( contraception , estrogen replacement therapy androgen supplement ) . Women must exogenous hormone therapy &gt; 16 week prior enrollment . 3 . Women pregnant breastfeeding . 4 . Women hemoglobin &lt; 9.0g/dL and/or hematocrit &lt; 28 % . 5 . Women unable complete , caretaker complete , dose administration card . 6 . Women , judgement investigator , unable comply protocol requirement . 7 . Women unable give write informed consent . 8 . Women comply abstain intercourse douche 48 hour prior study examination . 9 . Male transgender individual .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Sex</keyword>
	<keyword>Aging</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>post-menopausal woman HIV infection</keyword>
	<keyword>pre-menopausal woman HIV infection</keyword>
</DOC>